Form 4: CERO Therapeutics CDO Acquires 1.6M Stock Options

CERO Therapeutics Holdings, Inc.'s Chief Development Officer, Kristen Pierce, acquired 1,612,099 stock options exercisable at $0.055 per share.

Summary

• Kristen Pierce, Chief Development Officer of CERO Therapeutics Holdings, Inc., acquired 1,612,099 derivative securities in the form of stock options.
• The transaction date for this acquisition was January 7, 2026.
• Each stock option has an exercise price of $0.055.
• The options are exercisable starting January 7, 2026, and will expire on January 6, 2036.
• Following this transaction, Kristen Pierce beneficially owns 1,612,099 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive like the Chief Development Officer is generally viewed positively as it aligns management's long-term interests with those of shareholders, incentivizing performance and value creation. However, this filing alone does not provide information on the company's operational or financial performance.

Positives

• The grant of stock options to the Chief Development Officer aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and incentivize leadership by aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• Option grants are a standard component of executive compensation packages across industries, particularly in biotechnology where long-term development cycles are common. The specific size and exercise price would need to be compared against peer companies for a detailed assessment, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The option grant aims to align the Chief Development Officer's interests with long-term shareholder value creation, potentially leading to improved company performance.

Key Dates

Keywords

CERO Therapeutics Holdings, CERO, Stock Options, Insider Transaction, Executive Compensation, Form 4, Beneficial Ownership